Statistics

Total Visits

Views
Response to cabazitaxel in patients with metastatic castrationresistant prostate cancer (mCRPC) poorly responding to docetaxel42

Select a period of time:

Number of views in the range

Views
Response to cabazitaxel in patients with metastatic castrationresistant prostate cancer (mCRPC) poorly responding to docetaxel16

Views

Views
June 20250
July 202513
August 20250
September 20253
October 20250
November 20250
December 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States5
Brazil5
Bolivia1
Canada1
Côte d'Ivoire1
Colombia1
France1
United Kingdom1
 

Top cities views

Views
Dallas2
Abidjan1
Barranquilla1
Birmingham1
Brandon1
Dias dávila1
Downey1
Houston1
Joinville1
La Paz1